JP2022543702A5 - - Google Patents
Info
- Publication number
- JP2022543702A5 JP2022543702A5 JP2022508455A JP2022508455A JP2022543702A5 JP 2022543702 A5 JP2022543702 A5 JP 2022543702A5 JP 2022508455 A JP2022508455 A JP 2022508455A JP 2022508455 A JP2022508455 A JP 2022508455A JP 2022543702 A5 JP2022543702 A5 JP 2022543702A5
- Authority
- JP
- Japan
- Prior art keywords
- ligand
- seq
- binding domain
- receptor
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885093P | 2019-08-09 | 2019-08-09 | |
| US62/885,093 | 2019-08-09 | ||
| US202063005670P | 2020-04-06 | 2020-04-06 | |
| US63/005,670 | 2020-04-06 | ||
| PCT/US2020/045228 WO2021030149A1 (en) | 2019-08-09 | 2020-08-06 | Cell-surface receptors responsive to loss of heterozygosity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543702A JP2022543702A (ja) | 2022-10-13 |
| JP2022543702A5 true JP2022543702A5 (cg-RX-API-DMAC7.html) | 2023-08-01 |
| JP7739261B2 JP7739261B2 (ja) | 2025-09-16 |
Family
ID=74571174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022508455A Active JP7739261B2 (ja) | 2019-08-09 | 2020-08-06 | ヘテロ接合性の喪失に応答する細胞表面受容体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240173352A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4010377A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7739261B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220053587A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114585645B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020329881A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022002465A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150071A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290413A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022001711A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021030149A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| WO2021119489A1 (en) | 2019-12-11 | 2021-06-17 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
| WO2021168317A1 (en) * | 2020-02-20 | 2021-08-26 | Senti Biosciences, Inc. | Inhibitory chimeric receptor architectures |
| US12599665B2 (en) | 2020-08-13 | 2026-04-14 | A2 Biotherapeutics, Inc. | Gene fusions for control of genetically modified cells |
| US11433100B2 (en) | 2020-08-20 | 2022-09-06 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| EP4097486A4 (en) * | 2020-08-20 | 2023-09-06 | A2 Biotherapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER |
| EP4058474B1 (en) * | 2020-08-20 | 2024-05-08 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| IL304857A (en) | 2021-02-16 | 2023-10-01 | A2 Biotherapeutics Inc | Preparations and methods for treating HER2 POSITIVE cancer |
| CA3210801A1 (en) * | 2021-03-12 | 2022-09-15 | Michael S. HWANG | Engineered immune cells and uses thereof |
| WO2023014633A2 (en) * | 2021-08-03 | 2023-02-09 | A2 Biotherapeutics, Inc. | Vector systems for delivery of two polynucleotides and methods of making and using same |
| AU2023213691A1 (en) * | 2022-01-28 | 2024-09-05 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| AU2023216270A1 (en) * | 2022-02-04 | 2024-08-15 | Nkilt Therapeutics, Inc. | Chimeric ilt receptor compositions and methods |
| US20250177445A1 (en) * | 2022-03-08 | 2025-06-05 | A2 Biotherapeutics, Inc. | Engineered receptors specific to hla-e and methods of use |
| EP4519305A4 (en) * | 2022-05-02 | 2026-05-06 | Tscan Therapeutics Inc | Compositions of multiplexed T-lymphocyte receptors, polytherapies and their uses |
| WO2026006575A1 (en) * | 2024-06-26 | 2026-01-02 | A2 Biotherapeutics, Inc. | Immune cells with paired receptors and uses in treating autoimmunity |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100945108B1 (ko) * | 2001-06-13 | 2010-03-02 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (egfr)에 대한 인간모노클로날 항체 |
| US20030086929A1 (en) * | 2001-10-11 | 2003-05-08 | Tso J. Yun | Treatment of prostate cancer by inhibitors of ATP synthase |
| WO2006031221A1 (en) * | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2868121C (en) * | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| ES2688035T3 (es) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| CA2967222C (en) * | 2014-11-12 | 2023-10-31 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| CA3034093A1 (en) * | 2016-08-23 | 2018-03-01 | The Regents Of The University Of California | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
| KR102397771B1 (ko) * | 2016-09-23 | 2022-05-13 | 프레드 헛친슨 켄서 리서치 센터 | 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도 |
| MX2019003462A (es) | 2016-09-28 | 2019-08-16 | Gavish Galilee Bio Appl Ltd | Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer. |
| EP4759318A2 (en) * | 2017-04-14 | 2026-06-17 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| KR102742220B1 (ko) * | 2017-09-19 | 2024-12-17 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 항-hla-a2 항체 및 그 사용 방법 |
| PL3688155T3 (pl) * | 2017-09-28 | 2023-09-11 | Immpact-Bio Ltd. | Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar) |
| US11732257B2 (en) * | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
| EP3724225A1 (en) * | 2017-12-15 | 2020-10-21 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| BR112020022185A2 (pt) * | 2018-05-03 | 2021-02-02 | Juno Therapeutics Inc | terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase |
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| BR112021006100A2 (pt) | 2018-09-28 | 2021-07-20 | Immpact-Bio Ltd. | métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer |
| WO2021222576A1 (en) * | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
-
2020
- 2020-08-06 EP EP20853234.1A patent/EP4010377A4/en active Pending
- 2020-08-06 US US17/633,358 patent/US20240173352A1/en active Pending
- 2020-08-06 JP JP2022508455A patent/JP7739261B2/ja active Active
- 2020-08-06 BR BR112022002465A patent/BR112022002465A2/pt unknown
- 2020-08-06 MX MX2022001711A patent/MX2022001711A/es unknown
- 2020-08-06 AU AU2020329881A patent/AU2020329881A1/en active Pending
- 2020-08-06 CA CA3150071A patent/CA3150071A1/en active Pending
- 2020-08-06 KR KR1020227007569A patent/KR20220053587A/ko not_active Ceased
- 2020-08-06 WO PCT/US2020/045228 patent/WO2021030149A1/en not_active Ceased
- 2020-08-06 CN CN202080068565.7A patent/CN114585645B/zh active Active
-
2022
- 2022-02-07 IL IL290413A patent/IL290413A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bielamowicz et al. | Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | |
| Yousefi et al. | Immunotherapy of cancers comes of age | |
| JP2021526365A5 (cg-RX-API-DMAC7.html) | ||
| Seyedin et al. | Strategies for combining immunotherapy with radiation for anticancer therapy | |
| KR102186180B1 (ko) | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 | |
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| Comoli et al. | Development of adaptive immune effector therapies in solid tumors | |
| Seo et al. | IL21 therapy combined with PD-1 and Tim-3 blockade provides enhanced NK cell antitumor activity against MHC class I–deficient tumors | |
| WO2016081947A4 (en) | Determinants of cancer response to immunotherapy by pd-1 blockade | |
| Lettieri et al. | Progress and opportunities for immune therapeutics in osteosarcoma | |
| EP3666793A3 (en) | Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1 | |
| Duarte et al. | Gastric cancer: basic aspects | |
| JP2023552998A5 (cg-RX-API-DMAC7.html) | ||
| JP2021500406A5 (cg-RX-API-DMAC7.html) | ||
| JP2018513687A5 (cg-RX-API-DMAC7.html) | ||
| BR112018070741A2 (pt) | receptor de células t (tcr), tcr que se liga a um complexo hla-a*02, molécula de fusão a anti-cd3 de tcr, ácido nucleico, vetor de expressão, célula, célula de ocorrência não natural e/ou purificada e/ou projetada, composição farmacêutica, método de tratamento de um indivíduo humano em necessidade deste, formulação injetável para administração a um indivíduo humano, e método de produção de um tcr | |
| AU2018335274A1 (en) | HLA class II–restricted T cell receptors against mutated RAS | |
| JP2020512019A5 (cg-RX-API-DMAC7.html) | ||
| JP2018520679A5 (cg-RX-API-DMAC7.html) | ||
| JP2018532407A5 (cg-RX-API-DMAC7.html) | ||
| JP2017535292A5 (cg-RX-API-DMAC7.html) | ||
| JP2022537700A5 (cg-RX-API-DMAC7.html) | ||
| Kim et al. | Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics | |
| US10654934B2 (en) | Use of chimeric antigen receptor modified cells to treat cancer | |
| Rosenzweig et al. | Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis |